top of page

Stoke Therapeutics' CEO Ed Kaye on using RNA medicines to upregulate protein expression, and the company's progress in Dravet Syndrome

  • Aug 5, 2024
  • 1 min read

He describes the unique science that Stoke was founded on, how phase 1/2a data in Dravet appears to show they are reversing this genetic condition, and how he views the company's protein upregulation approach as a broader platform.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page